Format

Send to

Choose Destination
Metabolism. 2006 May;55(5 Suppl 1):S16-9.

Sulfonylureas and the risk of myocardial infarction.

Author information

1
Department of Clinical Epidemiology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.

Abstract

Patients with diabetes mellitus have an increased risk of coronary artery diseases such as myocardial infarction. Sulfonylureas are used in the treatment of diabetes mellitus and have been linked with adverse cardiovascular effects due to an apparent effect on myocardial ischemic preconditioning. Individual sulfonylureas differ pharmacologically and may have different effects. Although the hypotheses were stimulated by animal studies and experimental studies using intermediate end points, data on the possible clinical implications in humans remain sparse. However, recent data seem reassuring.

PMID:
16631805
DOI:
10.1016/j.metabol.2006.02.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center